Lee Jaehyeon, Kim Dal Sik, Lee Hye Soo, Choi Sam Im, Cho Yong Gon
Department of Laboratory Medicine, Chonbuk National University Medical School, Jeonju, Jeollabuk-do 54907, Republic of Korea.
Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeollabuk-do 54907, Republic of Korea.
Oncol Lett. 2017 Mar;13(3):1711-1713. doi: 10.3892/ol.2017.5668. Epub 2017 Feb 1.
Variant Philadelphia chromosome translocations involving chromosomes other than 9 and 22 have been reported in 5-10% of patients with chronic myeloid leukemia (CML). As part of the three-way variant t(9;22;11) in patients with CML, 11q24 is a novel region that has not previously been investigated. A 22-year-old male exhibiting chronic phase CML developed a recurrence of the same phase subsequent to the interruption of imatinib treatment and showed the same chromosomal abnormality, t(9;22;11)(q34;q11.2;q24), that was detected at the initial diagnosis. The recurrent CML responded well to imatinib therapy. These findings suggest that the three-way variant, t(9;22;11), involving 11q24 may be associated with a good prognosis and response to imatinib. This is the first report of three-way variant involving 11q24 in a patient with CML.
据报道，5%-10%的慢性髓性白血病（CML）患者存在涉及9号和22号以外染色体的费城染色体变异易位。作为CML患者中三向变异t(9;22;11)的一部分，11q24是一个此前未被研究过的新区域。一名表现为慢性期CML的22岁男性在伊马替尼治疗中断后出现了同一阶段的复发，并显示出与初始诊断时相同的染色体异常，即t(9;22;11)(q34;q11.2;q24)。复发性CML对伊马替尼治疗反应良好。这些发现表明，涉及11q24的三向变异t(9;22;11)可能与良好的预后及对伊马替尼的反应相关。这是首例关于CML患者中涉及11q24的三向变异的报告。
